BMS-193884 and BMS-207940 Bristol-Myers Squibb.
Copyright policy )BMS-193884 and BMS-207940 Bristol-Myers Squibb.
Bristol-Myers Squibb is developing BMS-193884, an oral endothelin antagonist, for the potential treatment of congestive heart failure (CHF) and pulmonary hypertension [206604]. The compound entered phase I trials in November 1996 [242721] and had progressed to phase II trials [399460], [441398]. Structural modifications led to the development of a second-generation analog, BMS-207940, a biphenylsulfonamide endothelin A receptor-selective antagonist, and the probable discontinuation of the first clinical candidate, BMS-193884 [446511]. By April 2002, BMS-207940 was in phase I trials [446511]. By March 2002, filing for NDA was expected to take place in 2004 at the earliest [452734].
- University of Göttingen Germany
Endothelin Receptor Antagonists, Heart Failure, Clinical Trials as Topic, Sulfonamides, Drug Industry, Hypertension, Pulmonary, Animals, Humans, Oxazoles
Endothelin Receptor Antagonists, Heart Failure, Clinical Trials as Topic, Sulfonamides, Drug Industry, Hypertension, Pulmonary, Animals, Humans, Oxazoles
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!